Na Li

Na Li

Auto-generated profile, based on publicly available information

Na Li

Institute of Agro-Food Science and Technology, Shandong Academy of Agricultural Sciences/Shandong Provincial Food for Special Medical Purpose Engineering Technology Research Center/Key Laboratory of Agro-Products Processing Technology of Shandong Province/Key Laboratory of Novel Food Resources Processing, Ministry of Agriculture and Rural Affairs, Jinan, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Food & Function
Verified
Journal Article
Closed access
PDF file
YWYali Wei
Yali Wei
YMYan Meng
Yan Meng
NLNa Li
Na Li
QWQian Wang
Qian Wang
LCLiyong Chen
Liyong Chen
Objective: The purpose of the systematic review and meta-analysis was to determine if low-ratio n-6/n-3 long-chain polyunsaturated fatty acid (PUFA) supplementation affects serum inflammation markers based on the current studies. Methods: PubMed, Embase and The Cochrane library databases were systematically searched to find randomized controlled trials (RCTs) on the effect of low-ratio n-6/n-3 PUFA intervention on inflammation markers up to July 2020. Data were pooled using standardized mean difference (SMD) and 95% confidence intervals (95% CI), with P value ≦ 0.05 as statistical significance. Results: Thirty-one RCTs were included in the meta-analysis. The analysis indicated that increasing low-ratio n-6/n-3 PUFA supplementation decreased the level of tumor necrosis factor-α (TNF-α) (SMD = −0.270; 95% CI: −0.433, −0.106; P = 0.001) and interleukin 6 (IL-6) (SMD = −0.153; 95% CI: −0.260, −0.045; P = 0.005). There were no significant effects on C-reactive protein (CRP) (SMD = −0.027; 95% CI: −0.189: 0.135; P = 0.741). Subgroup analysis indicated that there was a significant reduction in TNF-α serum concentration in subjects from Asia (SMD: −0.367; 95% CI: −0.579, −0.155; P = 0.001) and in subjects with diseases (SMD: −0.281; 95% CI: −0.436, −0.127; P < 0.001). In the subgroup of the n-6/n-3 ratio ≦5, low-ratio n-6/n-3 PUFA supplementation could decrease the level of TNF-α (SMD: −0.335; 95% CI: −0.552, −0.119; P = 0.002). Serum IL-6 decreased significantly in patients from the Europe subgroup (SMD: −0.451; 95% CI: −0.688, −0.214; P < 0.001), but not in Asia (SMD: −0.034; 95% CI: −0.226, 0.157; P = 0.724), North America (SMD: −0.115; 95% CI: −0.274, 0.044; P = 0.157) and Oceania (SMD: 0.142; 95% CI: −0.557, 0.842; P = 0.690). Conclusion: Low-ratio n-6/n-3 PUFA supplementation could decrease significantly the concentration of serum TNF-α and IL-6, but not decrease CRP concentration.

10 May 2019 in Food & Function
Verified
Journal Article
Closed access
PDF file
NLNa Li
Na Li
HYHao Yue
Hao Yue
MJMin Jia
Min Jia
WLWei Liu
Wei Liu
BQBin Qiu
Bin Qiu
TXTongcheng Xu
Tongcheng Xu
Objective: The aim of this meta-analysis was to investigate the effect of increasing dietary low-ratio n-6/n-3 polyunsaturated fatty acid (PUFA) intake on blood glucose and other related indicators. Methods: We systematically searched randomized controlled trials of low-ratio n-6/n-3 PUFA intervention on PubMed, Embase, Cochrane library and related references up to August 2018. The change values were calculated as the weighted mean difference (WMD) by using a random-effect model. Results: Eleven randomized controlled trials were included. No significant effect of dietary low-ratio n-6/n-3 PUFA supplementation was observed on fasting blood glucose (WMD: 0.057 mmol L−1; 95% CI: −0.090 to 0.204 mmol L−1), insulin (WMD: −0.757 mIU L−1; 95% CI: −2.419 to 0.904 mIU L−1), insulin resistance index (WMD: −0.201; 95% CI: −0.566 to 0.165), and glycosylated hemoglobin (WMD: −0.063%; 95% CI: −0.061 to 0.186%). Subgroup analysis showed that the effect of low-ratio n-6/n-3 PUFA on the reduction of the plasma insulin level in North America (WMD: −3.473 mIU L−1; 95% CI: −5.760 to −1.185 mIU L−1) was more obvious than that in Asian countries (WMD: −0.797 mIU L−1; 95% CI: −2.497 to 0.902 mIU L−1) and European countries (WMD: −0.063 mIU L−1; 95% CI: −0.061 to 0.186 mIU L−1). In the subgroup of diabetic subjects, low-ratio n-6/n-3 PUFA supplementation can decrease the plasma insulin level (WMD: −3.010 mIU L−1; 95% CI: −5.371 to −0.648 mIU L−1) and insulin resistance index (WMD: −0.460; 95% CI: −0.908 to −0.012). When the intervention period was longer than 8 weeks, low-ratio n-6/n-3 PUFA supplementation could also decrease the plasma insulin level (WMD: −2.782 mIU L−1; 95% CI: −4.946 to −0.618 mIU L−1). No significant publication bias was observed for all blood glucose and other related indicators as suggested by Begg's test and Egger's test. Conclusion: Our meta-analysis found that low-ratio n-6/n-3 PUFA supplementation could improve the glucose metabolism by reducing the insulin and insulin resistance in the diabetic patients. Low-ratio n-6/n-3 PUFA supplementation could reduce the plasma insulin level when the supplementation duration was longer than 8 weeks.